| Bioactivity | Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin (HY-121544)-susceptible Staphylococcus aureus. The MIC90 of nafithromycin against macrolide-resistant and telithromycin (HY-A0062)-insensitive Streptococcus pneumoniae is 0.12 mg/liter[1]. |
| CAS | 1691240-78-4 |
| Formula | C42H62N6O11S |
| Molar Mass | 859.04 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kohlhoff, et al. "In vitro activity of nafithromycin (WCK 4873) against Chlamydia pneumoniae." Antimicrobial Agents and Chemotherapy 65.9 (2021): 10-1128. |
Nafithromycin
CAS: 1691240-78-4 F: C42H62N6O11S W: 859.04
Nafithromycin (WCK 4873) is an orally available antibiotic that inhibits community-acquired pneumonia caused by Streptoc
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.